Frontage Holdings Corp. has promoted Dr. Abdul Mutlib to Chief Executive Officer, succeeding Frontage’s founder Dr. Song Li, who will remain as Executive Chairman of the Board of Directors.  Dr. John Lin has been promoted to President of Frontage Laboratories, Inc., the company’s wholly-owned subsidiary. As Executive Chairman, Dr. Li will continue to actively participate in the leadership of the company and focus on strategic growth opportunities.
 
Dr. Mutlib has been a member of Frontage’s executive team for more than 12 years, where he has overseen the company’s Preclinical (DMPK/Safety and Toxicology) business.  Dr. Lin has been an executive with Frontage for more than 15 years, responsible for building and leading the company’s extensive Bioanalytical and Biologics service capabilities.
 
Dr. Li said, “The promotions announced today are intended to optimize the leadership structure of the company both to reflect our current size as a global organization with over 1600 employees across 24 sites and to position us for further growth as we move into the future.  Abdul and John are proven leaders who have delivered phenomenal results for Frontage for over a decade, and they are each trusted and respected throughout the organization and pharmaceutical industry.  We have been preparing them for their new responsibilities for some time and Frontage is privileged to elevate them to their new roles.  This is an exciting time for Frontage, and I am looking forward to maintaining my close working relationship with Abdul and John as we continue to serve our stakeholders worldwide.”